← Back to headlines
Roche’s Vabysmo Shows Sustained Two-Year Efficacy for Macular Degeneration
Clinical data reveals that Roche’s Vabysmo injection maintains long-term visual benefits in patients with a difficult-to-treat form of neovascular age-related macular degeneration over a two-year period.
28 Aug, 07:00 — 28 Aug, 07:00
